不同疗程中成药对II-III期非小细胞肺癌2年生存率的影响
一项回顾性队列研究纳入614例II-III期非小细胞肺癌患者,比较不同疗程中成药及回生口服液治疗对2年生存率的影响。结果显示中成药治疗≥3个月和≥6个月者2年生存率高于<3个月者,回生口服液≥3个月者亦高于<3个月者,且随疗程延长2年生存率呈升高趋势。手术、化疗和回生口服液≥3个月为保护因素,男性和FIB≥4 g/L为危险因素。
要点
- 中成药治疗≥3个月与II-III期NSCLC患者2年生存率提高相关。
- 回生口服液≥3个月者2年生存率较高,且随疗程延长呈升高趋势。
- 手术、化疗为保护因素,男性和FIB≥4 g/L为预后危险因素。
核心结论
- 中成药治疗≥3个月可改善II-III期NSCLC患者的2年生存率。
- 回生口服液治疗≥3个月与2年生存率改善相关,且2年生存率随治疗时间延长呈升高趋势。
- 男性和FIB≥4 g/L是II-III期NSCLC患者2年生存率的危险因素。
研究设计与样本
- 按中成药治疗时长分为<3个月、≥3个月和≥6个月组,回生口服液分为<3个月和≥3个月及≥6个月组。
- 采用Kaplan-Meier法比较2年生存率,Cochran-Armitage趋势检验分析疗程与生存率改善的关系,Cox比例风险回归模型探索影响因素。
主要发现
- 中成药治疗≥3个月和≥6个月的患者2年生存率高于<3个月者,差异有统计学意义(p<0.05)。
- 回生口服液治疗≥3个月的患者2年生存率高于<3个月者(p<0.05)。
- 回生口服液治疗≥6个月者因总人数和结局改善人数过少,两组2年生存率差异无统计学意义(p>0.05)。
- Cochran-Armitage趋势检验显示2年生存率随回生口服液治疗时长增加呈升高趋势(p<0.05)。
关键数值与推荐
- Cox回归显示手术为保护因素[HR=0.48,95%CI(0.34,0.68)]。
- 化疗为保护因素[HR=0.46,95%CI(0.31,0.67)]。
- 回生口服液治疗≥3个月为保护因素[HR=0.48,95%CI(0.27,0.88)]。
- 男性为危险因素[HR=1.59,95%CI(1.01,2.50)]。
- FIB≥4 g/L为危险因素[HR=1.95,95%CI(1.37,2.77)]。
临床怎么用
- 对II-III期NSCLC患者,可考虑中成药治疗至少3个月以潜在改善2年生存率。
- 使用回生口服液时,建议疗程不少于3个月,并关注疗程延长带来的生存获益趋势。
- 临床应关注男性及纤维蛋白原≥4 g/L患者的预后风险,加强随访管理。
局限性
- 回顾性队列研究设计可能存在选择偏倚和混杂因素。
- 回生口服液≥6个月组样本量过少,该组生存率比较结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Chinese patent medicine is widely used among patients with malignant tumors, and current studies have shown that long-term treatment with Chinese patent medicine is related to improved outcomes of patients. Huisheng Oral Liquid is a kind of Chinese patent medicine with the effects of curing dispersion-thirst and dissipating blood stasis. However, little is known about how it affects the survival rate of patients. Thus, patients with stage II-III NSCLC (non-small-cell lung cancer) were chosen to participate in a retrospective cohort study, which was conducted to preliminarily investigate the effects of using Chinese patent medicine and Huisheng Oral Liquid for different treatment durations on patients' 2-year survival rate and explore the prognostic factors affecting the 2-year survival rate of those patients. Purpose: This work compares the effect of different durations of treatment with Chinese patent medicine and Huisheng Oral Liquid on the 2-year survival rate of patients with stage II-III NSCLC and explores the prognostic factors of the patients' 2-year survival rate. Methods: This retrospective cohort study included patients with non-small cell lung cancer stage II-III according to the 2015 NCCN Guidelines: Non-Small Cell Lung Cancer. The Kaplan-Meier method was used to compare the 2-year survival rate of patients treated with different durations of Chinese medicine and Huisheng Oral Liquid. The relationship between different treatment durations and degree of improvement of 2-year survival rate was explored using the Cochran-Armitage trend test. The Cox proportional-hazards regression models were used to explore factors affecting the 2-year survival rate of patients. Results: A total of 614 patients with stage II-III NSCLC diagnosed from January 2015 to December 2018 were included in this study. Patients treated with Chinese patent medicine were divided into three groups by treatment durations: < 3 months, ≥ 3 months, and ≥6 months, and those treated with Huisheng Oral Liquid were divided into < 3 months and ≥3 and ≥6 months. The results showed that ① the 2-year survival rate of patients treated with Chinese patent medicine for ≥3 months and ≥6 months was higher than that of patients treated for <3 months and the difference was statistically significant (p < 0.05). Further analysis of Huisheng Oral Liquid treatment revealed that ② the 2-year survival rate of patients treated with Huisheng Oral Liquid for ≥3 months was higher than that of patients treated for <3 months (p < 0.05). Because the total number of patients treated with Huisheng Oral Liquid for ≥6 months and the number of patients with improved outcomes were too small, there was no statistically significant difference in the 2-year survival rate between the two groups (p > 0.05). The results of the Cochran-Armitage trend test showed that the 2-year survival rate tended to increase with the duration of Huisheng Oral Liquid treatment (p < 0.05). ③ The Cox proportional -hazards regression model revealed that among all 614 patients, surgery [HR = 0.48, 95% CI = (0.34, 0.68)], chemotherapy [HR = 0.46, 95% CI = (0.31,0.67)], and treatment with Huisheng Oral Liquid for ≥3 months were protective factors [HR = 0.48, 95%CI = (0.27,0.88)], whereas male gender [HR = 1.59, 95% CI = (1.01, 2.50)] and FIB ≥4 g/L [HR = 1.95, 95% CI = (1.37, 2.77)] were risk factors. Conclusion: Chinese patent medicine treatment for ≥3 months showed an improvement in the 2-year survival rate of patients with stage II-III NSCLC. Patients treated with Huisheng Oral liquid for ≥3 months also showed an improvement in the 2-year survival rate, and the 2-year survival rate tended to increase as the treatment duration increased. Finally, male and FIB ≥ 4 g/L were risk factors for prognosis.
引用
- Wang L, Jia K, Li F, et al. Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study. Front Pharmacol. 2021. PMID: 34539404. doi:10.3389/fphar.2021.719802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。